Perrigo Co PLC (PRGO)

88.63
0.15 0.17
NYSE : Health Care
Prev Close 88.48
Open 88.28
Day Low/High 87.22 / 89.02
52 Wk Low/High 82.50 / 190.16
Volume 3.15M
Avg Volume 2.45M
Exchange NYSE
Shares Outstanding 143.28M
Market Cap 12.59B
P/E Ratio N/A
Div & Yield 0.58 (0.70%)

Latest News

These 5 Stocks Could Get Toxic Soon

These 5 Stocks Could Get Toxic Soon

It's time to unload these toxic stocks from your portfolio.

Perrigo (PRGO) Stock Slumps, Price Target Cut at Deutsche Bank

Perrigo (PRGO) Stock Slumps, Price Target Cut at Deutsche Bank

Deutsche Bank lowered its price target to $105 on Perrigo (PRGO) stock this morning.

Closing Bell: Perrigo Cuts Full-Year Guidance; U.S. Stocks Slip

Closing Bell: Perrigo Cuts Full-Year Guidance; U.S. Stocks Slip

U.S. stocks edged back from records highs set last week as resurfacing supply worries took a chunk out of crude prices.

Trending Tickers: RL, RAD, RIG, PRGO, KLAC

Trending Tickers: RL, RAD, RIG, PRGO, KLAC

Ralph Lauren shares surge on earnings beat amid lethargic market action.

More Squawk from Jim Cramer: Perrigo (PRGO) Quarter Was 'Problematic'

More Squawk from Jim Cramer: Perrigo (PRGO) Quarter Was 'Problematic'

Perrigo (PRGO) posted weak earnings for the 2016 second quarter and cut its full-year forecast, which Jim Cramer found 'disturbing.'

Why Hendrickson-Led Perrigo Is A Good Bet For Long Term Investors

Why Hendrickson-Led Perrigo Is A Good Bet For Long Term Investors

Despite cutting its full year guidance, the company continues to have a lot of potential upside.

Jim Cramer: Perrigo is Problematic

Jim Cramer: Perrigo is Problematic

Perrigo might have been in more of a decline than the market realized when it turned down Mylan's $26 billion offer for the company last year, says Jim Cramer.

Why I Feel Bearish About the Market

Why I Feel Bearish About the Market

I'm not inclined to make market calls, but the action on my screen is pushing me to a defensive stance.

Don't 'Catch a Falling Knife' with Perrigo

Don't 'Catch a Falling Knife' with Perrigo

The stock's tumbling to near a 52-week low, but charts suggest caution.

Perrigo (PRGO) Stock Slumps on Q2 Earnings Miss, Downbeat Guidance

Perrigo (PRGO) Stock Slumps on Q2 Earnings Miss, Downbeat Guidance

Perrigo (PRGO) reported earnings for the 2016 second quarter, falling short of estimates and cutting guidance for the year.

Perrigo (PRGO) Stock Gains Ahead of Tomorrow's Q2 Results

Perrigo (PRGO) Stock Gains Ahead of Tomorrow's Q2 Results

Perrigo (PRGO) is expected to report second-quarter earnings and revenue that fell from a year ago before tomorrow's market open.

Valeant Weighs $8B in Asset Sales to Address Debt

Valeant Weighs $8B in Asset Sales to Address Debt

Much to the relief of Bill Ackman and other investors, the Joe Papa-led company also reaffirmed its 2016 guidance on Tuesday.

Valeant Hangs on but Debt Pressures Remain

Valeant Hangs on but Debt Pressures Remain

The stock is up on earnings but there could be violations in agreements with creditors.

Valeant Shares Rally on Outlook, but Analysts Say Debt Worries Still Loom

Valeant Shares Rally on Outlook, but Analysts Say Debt Worries Still Loom

Analysts say Tuesday's earnings beat could spell trouble in terms of coping with its $31 billion worth of debt.

Jim Cramer's 'Mad Money' Recap: I'm Watching These Stocks Next Week

Jim Cramer's 'Mad Money' Recap: I'm Watching These Stocks Next Week

Cramer says he'll be watching Allergan, Tyson and Macy's earnings, among many others. Also, he explains why having money in the stock market is the best path to long-term rewards.

Analysts' Actions -- AthenaHealth, Pandora, PayPal, PulteGroup and More

Analysts' Actions -- AthenaHealth, Pandora, PayPal, PulteGroup and More

Here are Friday's top research calls, including downgrades for AthenaHealth, Pandora and PayPal, and an upgrade for PulteGroup.

It's Time to Sell These 5 Big Stocks This Summer

It's Time to Sell These 5 Big Stocks This Summer

Owning these stocks could be toxic to your portfolio.

Perrigo Announces Leadership Change In Rx Pharmaceuticals Segment

Perrigo Announces Leadership Change In Rx Pharmaceuticals Segment

Appoints John Wesolowski as Acting General Manager, Rx Pharmaceuticals

July 18 Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming Deadline In The Class Action Lawsuit Against Perrigo Company Plc

July 18 Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming Deadline In The Class Action Lawsuit Against Perrigo Company Plc

Law Offices of Howard G. Smith reminds investors of the upcoming  July 18, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class") of investors who purchased...

Jim Cramer's 'Mad Money' Recap: Stock Prices Just Getting Started

Jim Cramer's 'Mad Money' Recap: Stock Prices Just Getting Started

Listen to what the companies are actually telling you. Then assess what that might mean for the future, Cramer says.

Pricing Stress may Weigh on Generic Drugmakers Ahead of Q2 Earnings

Pricing Stress may Weigh on Generic Drugmakers Ahead of Q2 Earnings

Endo Pharmaceuticals is most under pressure, analysts say.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Perrigo Company Plc Of Class Action Lawsuit And A Lead Plaintiff Deadline Of July 18, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Perrigo Company Plc Of Class Action Lawsuit And A Lead Plaintiff Deadline Of July 18, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Perrigo Company plc ("Perrigo") (NYSE: PRGO) between April 21,...